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Abstract
Background: Hypertension is the most prevalent cardiovascular long-term condition in the UK and is associated
with a high rate of multimorbidity (MM). Multimorbidity increases with age, ethnicity and social deprivation.
Previous studies have yielded conflicting findings about the relationship between MM and blood pressure (BP)
control. Our aim was to investigate the relationship between multimorbidity and systolic blood pressure (SBP) in
patients with hypertension.
Methods: A cross-sectional analysis of anonymised primary care data was performed for a total of 299,180 adult
patients of whom 31,676 (10.6 %) had a diagnosis of hypertension. We compared mean SBP in patients with
hypertension alone and those with one or more co-morbidities and analysed the effect of type of comorbidity on
SBP. We constructed a regression model to identify the determinants of SBP control.
Results: The strongest predictor of mean SBP was the number of comorbidities, β −0.13 (p < 0.05). Other predictors
included Afro-Caribbean ethnicity, β 0.05 (p < 0.05), South Asian ethnicity, β −0.03 (p < 0.05), age, β 0.05 (p < 0.05),
male gender, β 0.05 (p < 0.05) and number of hypotensive drugs β 0.06 (p < 0.05). SBP was lower by a mean of
2.03 mmHg (−2.22, −1.85) for each additional comorbidity and was lower in MM regardless of the type of
morbidity.
Conclusion: Hypertensive patients with MM had lower SBP than those with hypertension alone; the greater the
number of MM, the lower the SBP. We found no evidence that BP control was related to BP targets, medication
category or specific co-morbidity. Further research is needed to determine whether consultation rate, “white-coat
hypertension” or medication adherence influence BP control in MM.
Background
Multimorbidity (MM), the presence of more than one
long-term condition (LTC), is common, increases with
age, occurs 10–15 years earlier in deprived populations
and is twice as prevalent in the non-white population
[1–3]. The prevalence of MM is dependent on the defin-
ition [4]. A fairly narrow definition of MM has been
adopted by the Quality and Outcomes Framework (QOF),
a pay-for-performance incentive scheme introduced into
the United Kingdom in 2004 with a focus on a series of
clinical targets for the management of LTCs [5]. This
scheme currently incorporates targets for 19 LTCs and in
terms of blood pressure it is important to note that there
are different BP targets for different conditions. The esti-
mated prevalence of LTCs contained within the QOF in
England is 16 % [5] and patients with a combination of
these conditions account for 32 % of consultations in pri-
mary care [1]. Casting a wider net to include LTCs not
within QOF, these proportions increase to 58 and 78 % re-
spectively [1]. From the patient perspective, multimorbid-
ity is associated with reduced functional status, poorer
quality of life, increased mortality [5] and an increased use
of inpatient and outpatient services [2].
Hypertension is the most common long-term condi-
tion in the UK, with 13.7 % of the population on the
QOF hypertension register [6]. The true prevalence of
hypertension is thought to be much higher with popula-
tion studies such as the Health Survey for England esti-
mating prevalence as high as 31 % in men and 27 % in
women [7]. Hypertension is associated with a high level
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of multimorbidity and 78 % of hypertensive patients
have at least one other LTC [2]. Hypertension is the sin-
gle most important risk factor for the development of
cardiovascular disease (CVD), with the risk of develop-
ing CVD doubling for every 20 mmHg increase in sys-
tolic blood pressure [8]. Hypertension is responsible for
an estimated 51 % of stroke deaths and 45 % of IHD
deaths worldwide [9].
Uncertainty exists about the relationship between
blood pressure control and MM. Paulsen et al. [10] com-
pared blood pressure control in over 37,000 Danish
hypertensive patients and determined the proportion
reaching their target blood pressure (BP), stratified ac-
cording to multimorbidity. They demonstrated better BP
control for some comorbidities (CVD, chronic obstruct-
ive pulmonary disease, osteoporosis, congestive heart
failure and atrial fibrillation) and worse control for
others (diabetes, diabetes with CVD, psychiatric disease,
asthma and cancer). Although the sample size was large,
findings may have been influenced by selection bias
(48 % of the catchment population did not contribute
data) and a relatively homogenous population in terms
of ethnicity and deprivation. Two UK studies both con-
cluded that BP control was improved in the presence of
accompanying comorbidity but only cardiovascular co-
morbidities were included [3, 11].
Studies looking at health outcomes in other long-term
conditions suggest worse outcomes compared to those
with no LTCs. MM was shown to be a poor prognostic
factor with regards to mortality and treatment complica-
tions in patients with cancer [12, 13], cardiovascular dis-
ease [14], diabetes [15] and common mental health
problems [16]. Given this trend one would expect worse
BP control with increased MM, contrary to the findings
in the studies in hypertensive patients mentioned above.
Therefore, we aimed to determine the relationship be-
tween systolic blood pressure (SBP) which is associated
with greater CVD risk compared to diastolic BP [17] in
patients with hypertension and the number and type of
multimorbidity. In particular we sought to identify
whether combinations of multimorbidity such as cardio-
vascular, psychiatric or respiratory conditions influenced
the relationship with BP control.
Method
Data for this study were collected from Lambeth Data-
Net, a patient level primary care database containing in-
formation on patient demographics, QOF conditions,
clinical measurements and medication. We used data
from the year 2011/12 covering 299,180 patients over
18 years old registered at 51 of the 52 general practices
in Lambeth (the remaining practice had an incompatible
computer system). Lambeth is the ninth most deprived
borough in London [18] and has the third highest
proportion of Black African and Caribbean people in the
UK at 25.9 % [19]. The patient characteristics for this
population are shown in Table 1.
There were 31,793 persons on the QOF hypertension
register, giving a recorded prevalence of 10.6 % in the
adult population. This value is lower than estimates of
national prevalence and reflects the relatively young
population in Lambeth [20]. Data that were incorrectly
coded and patients with no record of a BP reading or
implausible BP readings (diastolic <30 or >200 mmHg;
systolic <50 or >300 mmHg;), were excluded (n = 117).
Inclusion of BP values was not influenced by the process
of exception reporting, whereby GPs exclude some pa-
tients from QOF targets; our study included all BP data,
regardless of whether the GP had exception reported the
patient. Our final analysis was conducted on the
remaining 31,676 cases with a recorded diagnosis of
hypertension.
We selected twelve QOF conditions commonly in-
cluded in studies of multimorbidity [2]. These included
six cardiovascular comorbidities: ischaemic heart disease
(IHD), heart failure, diabetes mellitus (DM), chronic kid-
ney disease (CKD), stroke and atrial fibrillation (AF);
three mental health comorbidites: depression, serious
mental illness (SMI) and dementia; two respiratory co-
morbidities: chronic obstructive pulmonary disease
(COPD) and asthma; and epilepsy. We then explored
the pattern of BP control in hypertensive patients with
and without multimorbidity and according to multimor-
bidity number, type and combination.
We calculated mean SBP for all patients with hyper-
tension, using the last recorded SBP for each patient,
and stratified the sample according to the presence of
comorbidity, the number of comorbidities and their type.
We used the analysis of covariance (ANCOVA) method
to adjust the mean SBP values for age, ethnicity and gen-
der. We also constructed linear regression models in
order to identify the most important determinants of
SBP in patients with hypertension using the ‘enter’ re-
gression method. The following potential predictor vari-
ables were considered: age, gender, deprivation, ethnicity
Table 1 Patient characteristics of the study population
Patient characteristics Mean (SD)/proportion
Age (years) 63.88 (14.2)
Male 46.25 %
Female 53.75 %
IMD-2010 31.5 (8.7)
Number of comorbidities 0.83 (1.1)
White 43.9 %
Afro-Caribbean 33.7 %
South Asian 6.0 %
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(White, Afro-Caribbean, South Asian and ‘Other’ on self
reported ethnicity), medication (number of classes of
hypotensive agents prescribed: ACE inhibitors, beta-
blockers, calcium antagonists and diuretics) and number
of comorbidities. Variables were only included in the
model if they were found to be significant on univariate
analysis, p < 0.1. Because of multiple testing, we only
considered predictor variables in the regression model
as significant if p <0.01. We conducted tests of colinear-
ity and for the normality of residuals in order to ensure
robustness of the model. Our analysis was conducted
using SPSS version 20 [21].
Results
In our sample of patients with hypertension, 16,140 (51 %)
had one or more of the QOF co-morbidities. Patients with
hypertension alone had a mean SBP of 139.4 mmHg (95 %
CI; 139.2, 139.7) whereas those with any multimorbidity
had a mean SBP of 136.3 mmHg (95 % CI; 136.1, 136.6).
Patients with MM were further categorised by the num-
ber of comorbidities in addition to hypertension. The
mean SBP of those with one comorbidity (n = 9626) was
137.1 mmHg (95 % CI 136.7, 137.4), for those with two
comorbidities (n = 4028) was 136.0 mmHg (95 % CI 135.5,
136.5) and for those with three comorbidities was
134.3 mmHg (95 % CI 133.5, 135.2). Full results for pa-
tients with up to 5 or more comorbidities are displayed in
Fig. 1.
The specific comorbidity made no difference to the
mean SBP. There were no significant differences in
blood pressure control between any of the individual co-
morbidities (Fig. 2) or between any of the comorbidity
groupings in patients with hypertension plus two comor-
bidities (n = 4028) of cardiovascular, mental health and
respiratory diseases (Fig. 3).
In our regression model, the strongest predictor of
mean systolic BP was the number of comorbidities, B
value =−2.03 (p < 0.05), beta =−0.13 (p < 0.05). Other
significant predictors included the number of different
hypotensive drug classes prescribed, ethnicity, gender
and age (Table 2). The B values in Table 2 demonstrate
the direct relationship between ethnicity and mean SBP;
for example, the B value of 1.74 for Afro-Caribbean pa-
tients indicates that the mean SBP in the Afro-Caribbean
sample was 1.74 mmHg higher than that of the White ref-
erence group. Social deprivation (IMD-2010) was not a
significant determinant of systolic BP. There was no evi-
dence of colinearity between the variables with a variance
inflation factor (VIF) varying between 1.02 and 1.20 for
the different variables. Analysis of the residuals showed a
normal distribution with no relationship between the re-
siduals (Durbin-Watson statistic 1.96).
Discussion
Patients with hypertension with one or more comorbidi-
ties had a lower mean SBP than those with hypertension
alone. The mean SBP was lower in patients with a greater
number of comorbidities. Following adjustment for age,
gender and ethnicity, the mean SBP was 2.03 mmHg
lower for each additional morbidity. The improvement in
BP control was independent of the type of comorbidity or
comorbidity combination.
Our data provided further information on the factors
with the potential to influence BP control. Firstly, we
considered the effect of different QOF targets for SBP.
We found no difference in mean SBP in patients with
CKD or DM, both conditions for which the SBP QOF
target is lower than for hypertension alone. Secondly, we
found no evidence that the relationship between MM
and SBP was mediated through the use of additional
classes of hypotensive medication. Patients prescribed
more classes of hypotensive agents had higher mean
SBP. This is likely to be the result of reverse causality:
that higher SBP resulted in more intensive hypotensive
prescribing. Thirdly, we explored whether the overall re-
lationship between MM and SBP might differ according
128
130
132
134
136
138
140
142
0 1 2 3 4 5
M
ea
n
 S
ys
to
lic
 B
lo
o
d
 P
re
ss
u
re
 
(m
m
H
g
)
Number of comormidities
Fig. 1 The relationship between number of comorbidities and mean systolic blood pressure in patients with hypertension. Error bars show the
95 % confidence interval of the mean
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to specific multimorbidity combinations. Morbidities
which show a common pathophysiology, risk factor pro-
file or management plan have been termed ‘concordant’;
those that do not have been termed ‘discordant’ and in
some studies these have been associated with poorer
health outcomes [22]. There have been other studies,
however where no association between ‘concordant’ and
‘discordant’ were found [23–25] and we found no differ-
ence in SBP attributable to concordant or discordant
MM combinations with all comorbidities were associ-
ated with lower SBP compared to hypertension alone,
regardless of the type of comorbidity (Figs. 2 and 3). The
results demonstrate the achievement of primary care in
controlling major risk factors of CVD in patients with
multimorbidity and multiple riskfactors.
Comparison with existing literature
Our results differed from the Danish study [10] in that we
found a consistent reduction in SBP associated with co-
morbidity and that higher numbers of comorbidities were
associated with a lower SBP. The difference in our results
may be attributable to our more detailed analysis based on
a continuous outcome variable (SBP) rather than dichoto-
mised data - the Danish study only identified success or
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Fig. 2 SBP values for patients with hypertension alone and with hypertension plus one comorbidity. (HTN = hypertension, SMI = serious mental
illness, IHD = ischaemic heart disease, DM = diabetes, CKD = chronic kidney disease, AF = atrial fibrillation, COPD = chronic obstructive pulmonary
disease). Error bars show the 95 % confidence interval of the mean (n = 9626)
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Fig. 3 SBP values for patients with hypertension plus two comorbidities from the following groupings; CVD = cardiovascular disease (ischaemic
heart disease, heart failure, diabetes, chronic kidney disease, stroke and atrial fibrillation) MH =mental health conditions (depression, dementia
and serious mental illness), Resp = respiratory disease (chronic obstructive pulmonary disease and asthma). Error bars show the 95 % confidence
interval of the mean (n = 4028)
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failure in achieving a BP target. Furthermore, by achieving
high population coverage, our study had less potential for
selection bias.
Other studies produced findings consistent with ours
[2, 3, 11, 26] in terms of BP control in cardiovascular
MM, but we were able to extend these findings by includ-
ing respiratory and mental health comorbidities and epi-
lepsy. In total, we analysed data for six non-cardiovascular
MM and for each condition, we found a consistent associ-
ation between additional co-morbidities and reductions in
mean ‘‘SBP”.
Strengths and limitations
Our study minimised selection bias though a large sam-
ple size covering 96 % of patients registered to practices
in one inner London borough. This sample included a
wide diversity in deprivation and ethnicity. We confined
our analysis to QOF conditions which standardised the
GP coding of these conditions. There are limitations in
the interpretation of QOF data as it was not designed as
a research tool and therefore the data are not externally
validated [27] and inaccuracy in coding may also con-
tribute to limitations of this data [28]. Our findings are
likely to apply to the management of hypertension in
other urban areas characterised by relatively high social
deprivation and multi-ethnicity but it is less clear the ex-
tent to which they apply to more prosperous or predom-
inantly mono-ethnic areas.
We considered other factors which we were unable to
study because of the limitations of our dataset and
which may have influenced the relationship between
MM and SBP control. We were only able to use the last
recorded SBP and not calculate an average over a period
of time which may have given a better indication of
overall SBP control. Patients with a greater number of
comorbidities are likely to have higher consultation rates
with health care professionals, be exposed to more op-
portunities for adjusting medication and discussing life-
style measures, and more frequent BP recordings which
in turn might reduce the ‘white coat’ effect on blood
pressure readings and result in lower recorded SBP.
Burstyn et al. suggested that patients who have their BP
taken regularly are ‘trained’ and have a lower BP reading
compared to those who are ‘untrained’ or not used to
having their BP taken [29]. However, other studies have
suggested that more frequent readings do not make a
difference in ‘white-coat hypertension’ [30]. Alterna-
tively, multimorbidity may be linked with increased ad-
herence to hypotensive medication because of the
perceived seriousness of multiple conditions [31]. Most
patients with hypertension alone are asymptomatic, and
this is likely to influence adherence [32]. Other studies,
however, have found an association between multimor-
bidity and reduced adherence [16, 33]. Although we
were able to record the category of hypotensive medica-
tion, we were not able to convert this to a standardised
measure of daily dosage nor were we able to measure
medication adherence. Furthermore, we were unable to
access data on the consultation rates for patients with
different morbidities.
Conclusion
Our findings demonstrate that overall BP control is im-
proved in multimorbidity patients seen in primary care.
The findings are reassuring given the growing number
of people with MM, but whether improved intermediate
outcome measures in patients with MM translate into
improved cardiovascular health outcomes needs to be
explored. Following these findings which in some ways
were counter-intuitive, we plan to extend out work to
look at other intermediate outcomes such as HbA1c and
cholesterol levels. National data on consultation rates
have not been produced since 2008 [34] and in future
work we plan to collect local data on consultation rates
to explore this important confounder. The role of multi-
morbidity in the management of cardiovascular risk fac-
tors is complex but is an important component of
primary care and needs to be reflected in clinical guid-
ance, training and improvement initiatives [35, 36].
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Table 2 Predictors of SBP (unadjusted and adjusted) using multivariable regression
Predictors B value, unstandardised (95 % confidence intervals) Beta value, standardised p-value
Number of comorbidities −2.03 (−2.22, −1.85) −0.13 <0.001
Number of classes of antihypertensive drugs 0.82 (0.66, 0.97) 0.06 <0.001
Age (years) 0.06 (0.04, 0.07) 0.05 <0.001
Gender (reference group male) −1.63 (−2.00, −1.27) −0.05 <0.001
South Asian ethnicity (reference group white) −1.83 (−2.60, −1.07) −0.03 <0.001
Afro Caribbean ethnicity (reference group white) 1.74 (1.35, 2.14) 0.05 <0.001
IMD score (IMD-2010) 0.008 (−0.01, 0.03) 0.004 0.043
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